PVLA
NASDAQ · Biotechnology
Palvella Therapeutics Inc
$113.10
+0.47 (+0.42%)
Open$115.70
Previous Close$112.63
Day High$116.60
Day Low$110.96
52W High$151.18
52W Low$20.20
Volume—
Avg Volume311.8K
Market Cap1.62B
P/E Ratio—
EPS$-4.16
SectorBiotechnology
Analyst Ratings
Strong Buy
23 analysts
Price Target
-53.3% upside
Current
$113.10
$113.10
Target
$52.81
$52.81
$42.56
$52.81 avg
$76.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 566.81M | 499.65M | 158.95M |
| Net Income | -113,650,693 | -90,167,157 | 26.26M |
| Profit Margin | -57.3% | -54.5% | 16.5% |
| EBITDA | -93,594,513 | -78,380,454 | 46.23M |
| Free Cash Flow | — | — | 10.92M |
| Rev Growth | +13.4% | +13.4% | +20.5% |
| Debt/Equity | 0.63 | 0.63 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |